Pfizer Animal Health is offering US$100,000 in grant funding available to study treatment of swine respiratory disease.
The company is seeking research proposals to support the continued study of the clinical efficacy of Draxxin (tulathromycin) Injectable Solution, a macrolide for the treatment of swine respiratory disease (SRD), the leading cause of swine mortality in the United States.
The animal health company will provide up to four grants, US$100,000 in total, for clinical research on the use of the solution as part of an overall disease treatment and control plan that demonstrates a direct benefit to swine health. The injectable solution will be provided to study investigators at no cost.
"Through these research grants, we are seeking to further our understanding of Draxxin's real world efficacy and its practical uses," said Shelley Stanford, director, US Pork Technical Services at Pfizer.
Complete criteria and proposal requirements can be found at Pfizer Draxxin. A Pfizer Animal Health committee will review applications and alert recipients in December 2012.
• Pfizer Animal Health